LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND

The present invention provides a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenera...

Full description

Saved in:
Bibliographic Details
Main Authors KIELBASA, William Brian, MERGOTT, Dustin James
Format Patent
LanguageEnglish
Published 26.10.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodegenerative tauopathies, such as Alzheimer's disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy.
Bibliography:Application Number: US202118005245